Cemiplimab-rwlc
ImmunotherapyApproved for: NSCLC NSCLC patients tumors with high PD-L1 expression and without EGFR, ALK, ROS1 aberrations. Related Research News FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLCClinical Research Demonstrates Positive Impact of Genomic Testing for Patients with...